BRPI0914004A2 - agentes de aglutinação de receptor notch1 e métodos de uso mesmo - Google Patents

agentes de aglutinação de receptor notch1 e métodos de uso mesmo

Info

Publication number: BRPI0914004A2
Authority: BR; Brazil
Prior art keywords: receptor binding; binding agents; use methods; same use; notch1 receptor
Prior art date: 2008-07-08

Application number

BRPI0914004A

Other languages

English (en)

Inventor

Austin L Gurney

Fumiko Takada Axelrod

Maureen Fitch Bruhns

Timothy Charles Hoey

Original Assignee

Oncomed Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-07-08

Filing date

2009-07-08

Publication date

2015-11-17

2009-07-08 Application filed by Oncomed Pharm Inc filed Critical Oncomed Pharm Inc

2015-11-17 Publication of BRPI0914004A2 publication Critical patent/BRPI0914004A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/18—Kallidins; Bradykinins; Related peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/22—Tachykinins, e.g. Eledoisins, Substance P; Related peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Microbiology (AREA)
Cell Biology (AREA)
Oncology (AREA)
Mycology (AREA)
Zoology (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Endocrinology (AREA)
General Engineering & Computer Science (AREA)
Pathology (AREA)
Radiology & Medical Imaging (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

BRPI0914004A 2008-07-08 2009-07-08 agentes de aglutinação de receptor notch1 e métodos de uso mesmo BRPI0914004A2 (pt)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US7909508P	2008-07-08	2008-07-08
US11270108P	2008-11-07	2008-11-07
US11269908P	2008-11-07	2008-11-07
PCT/US2009/003995 WO2010005567A2 (en)	2008-07-08	2009-07-08	Notch1 receptor binding agents and methods of use thereof

Publications (1)

Publication Number	Publication Date
BRPI0914004A2 true BRPI0914004A2 (pt)	2015-11-17

Family

ID=41507637

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
BRPI0914007A BRPI0914007A2 (pt)	2008-07-08	2009-07-08	anatagonistas e agentes de ligação de notch e métodos para uso dos mesmos
BRPI0914004A BRPI0914004A2 (pt)	2008-07-08	2009-07-08	agentes de aglutinação de receptor notch1 e métodos de uso mesmo

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
BRPI0914007A BRPI0914007A2 (pt)	2008-07-08	2009-07-08	anatagonistas e agentes de ligação de notch e métodos para uso dos mesmos

Country Status (31)

Country	Link
US (11)	US8226943B2 (pt)
EP (4)	EP2899211A1 (pt)
JP (2)	JP5560271B2 (pt)
KR (2)	KR101682490B1 (pt)
CN (3)	CN104402998A (pt)
AU (2)	AU2009269095B2 (pt)
BR (2)	BRPI0914007A2 (pt)
CA (2)	CA2729602A1 (pt)
CO (2)	CO6390041A2 (pt)
CR (1)	CR20110069A (pt)
CY (2)	CY1116195T1 (pt)
DK (2)	DK2307051T3 (pt)
DO (2)	DOP2011000004A (pt)
EA (2)	EA201170157A1 (pt)
ES (2)	ES2535614T3 (pt)
HR (2)	HRP20150256T1 (pt)
IL (2)	IL210222A (pt)
MA (2)	MA32448B1 (pt)
ME (2)	ME02148B (pt)
MX (2)	MX2011000233A (pt)
MY (2)	MY159815A (pt)
NZ (2)	NZ590127A (pt)
PL (2)	PL2307459T3 (pt)
PT (2)	PT2307051E (pt)
RS (2)	RS53924B1 (pt)
SG (2)	SG192468A1 (pt)
SI (2)	SI2307051T1 (pt)
SM (2)	SMT201500047B (pt)
UA (1)	UA101672C2 (pt)
WO (2)	WO2010005566A2 (pt)
ZA (2)	ZA201009280B (pt)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6984522B2 (en) *	2000-08-03	2006-01-10	Regents Of The University Of Michigan	Isolation and use of solid tumor stem cells
US9540694B2 (en) *	2006-05-19	2017-01-10	The Johns Hopkins University	HEYL as a therapeutic target and a diagnostic marker for neoplasia and uses therefor
WO2007145840A2 (en)	2006-06-13	2007-12-21	Oncomed Pharmaceuticals, Inc.	Compositions and methods for diagnosing and treating cancer
CA2670992C (en)	2006-12-18	2017-11-21	Genentech, Inc.	Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases
JP5618544B2 (ja)	2007-01-24	2014-11-05	オンコメッドファーマシューティカルズインコーポレイテッド	癌の診断および処置のための組成物および方法
US9132189B2 (en)	2008-07-08	2015-09-15	Oncomed Pharmaceuticals, Inc.	Notch1 binding agents and methods of use thereof
NZ590127A (en)	2008-07-08	2012-11-30	Oncomed Pharm Inc	Notch1 receptor binding agents and methods of use thereof
BRPI0913827A2 (pt) *	2008-10-01	2020-12-29	Genentech, Inc	Anticorpo monoclonal, método para inibir a atividade de notch2, método para tratar uma doença, método para tratar uma malignidade, método para tratar um melanoma, usos de um anticorpo e anticorpo nrr anti-notch2
CN102686610A (zh)	2009-06-18	2012-09-19	辉瑞公司	抗刻缺蛋白-1抗体
CA2775880A1 (en) *	2009-09-30	2011-04-07	Genentech, Inc.	Anti-notch3 antagonist antibodies to treat gamma secretase inhibitor responsive and anti-notch1 antagonist antibody unresponsive t-cell leukemias
ES2700450T3 (es)	2009-10-16	2019-02-15	Oncomed Pharm Inc	Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensores
AU2011205316B2 (en) *	2010-01-13	2015-05-28	Oncomed Pharmaceuticals, Inc.	Notch1 binding agents and methods of use thereof
SG10201501496TA (en)	2010-03-01	2015-04-29	Tau Therapeutics Llc	Cancer diagnosis and imaging
PE20130460A1 (es) *	2010-05-03	2013-04-26	Genentech Inc	Composiciones y metodos para el diagnostico y tratamiento de tumores
JP6016800B2 (ja)	2010-12-15	2016-10-26	ワイス・エルエルシー	抗ノッチ１抗体
US20130058947A1 (en) *	2011-09-02	2013-03-07	Stem Centrx, Inc	Novel Modulators and Methods of Use
US20130064814A1 (en) *	2011-09-12	2013-03-14	Lloyd S. Gray	Antagonists of products of the hs.459642 unigene cluster for the inhibition of proliferation, development or differentiation of stem cells including cancer stem cells
SI3485903T1 (sl)	2011-09-23	2023-02-28	Mereo Biopharma 5, Inc.	Sredstva, ki vežejo VEGF/DLL4, in njihove uporabe
AR088048A1 (es) *	2011-10-04	2014-05-07	Univ Columbia	Señuelos notch1 humanos
WO2013052155A1 (en)	2011-10-05	2013-04-11	Genentech, Inc.	Methods of treating liver conditions using notch2 antagonists
CA2864197A1 (en) *	2011-11-16	2013-05-23	Oncomed Pharmaceuticals, Inc.	Human notch receptor mutations and their use
KR101535219B1 (ko) *	2011-11-18	2015-07-09	한국생명공학연구원	Ｎｏｔｃｈ３에 대한 인간 단일클론항체
US9534058B2 (en)	2012-02-08	2017-01-03	Abbvie Stemcentrx Llc	Anti-CD324 monoclonal antibodies and uses thereof
EP2849785A4 (en) *	2012-05-16	2015-12-16	Oncomed Pharm Inc	METHOD FOR THE TREATMENT OF CANCER WITH NOTCH2 / 3 ANTIBODIES
WO2014028446A1 (en)	2012-08-13	2014-02-20	Genentech, Inc.	Anti-jagged anitbodies and methods of use
CA2884309A1 (en)	2012-09-07	2014-03-13	Massachusetts Eye And Ear Infirmary	Methods and compositions for regenerating hair cells and/or supporting cells from differentiated cochlear cells or differentiated utricular cells by modulation of notch and cmyc activity
US20150232570A1 (en) *	2012-09-21	2015-08-20	Oncomed Pharmaceuticals, Inc.	Methods of Treating Hematological Malignancies with Notch1 Antibodies
HK1208371A1 (en) *	2012-10-09	2016-03-04	桑比欧公司	Methods and compositions for treatment of retinal degeneration
CA2889638A1 (en)	2012-10-31	2014-05-08	Oncomed Pharmaceuticals, Inc.	Methods and monitoring of treatment with a dll4 antagonist
TW201726746A (zh)	2012-11-07	2017-08-01	輝瑞股份有限公司	抗切口３（ａｎｔｉ-ｎｏｔｃｈ３）抗體及抗體-藥物共軛體
EP2935330B1 (en) *	2012-12-19	2019-04-24	Aveo Pharmaceuticals, Inc.	Anti-notch3 antibodies
GB201302447D0 (en)	2013-02-12	2013-03-27	Oxford Biotherapeutics Ltd	Therapeutic and diagnostic target
SG10201803131TA (en) *	2013-02-18	2018-06-28	Univ Health Network	Methods for generating hepatocytes and cholangiocytes from pluripotent stem cells
EP2970468B1 (en)	2013-03-13	2021-07-07	Novartis AG	Notch2 binding molecules for treating respiratory diseases
EP2970479B1 (en) *	2013-03-14	2019-04-24	Novartis AG	Antibodies against notch 3
KR20150130466A (ko) *	2013-03-15	2015-11-23	온코메드 파마슈티칼스, 인크.	췌장암을 치료하는 방법
PE20151750A1 (es)	2013-03-15	2015-12-07	Genentech Inc	Composiciones y metodos para el diagnostico y tratamiento del cancer hepatico
CA2936565C (en)	2014-02-12	2020-08-11	Genentech, Inc.	Anti-jagged1 antibodies and methods of use
US20170023576A1 (en) *	2014-04-04	2017-01-26	Oncomed Pharmaceuticals, Inc.	Notch3 antibodies and uses thereof
CN106488775A (zh)	2014-07-11	2017-03-08	基因泰克公司	Notch途径抑制
GB201416832D0 (en) *	2014-09-24	2014-11-05	Glaxosmithkline Plc	Methods of treatment
WO2016069906A1 (en)	2014-10-29	2016-05-06	Massachusetts Eye And Ear Infirmary	Efficient delivery of therapeutic molecules to cells of the inner ear
DK3212233T3 (da)	2014-10-31	2020-07-27	Oncomed Pharm Inc	Kombinationsterapi til behandling af sygdom
CN105986001B (zh) *	2015-02-12	2019-12-03	上海交通大学	一种基于膜结合蛋白和荧光互补的高通量猎物拮抗剂筛选方法
JP6784687B2 (ja)	2015-02-24	2020-11-11	ザリージェンツオブザユニバーシティオブカリフォルニア	結合誘発型転写スイッチ及びその使用方法
TWI609687B (zh) *	2015-04-14	2018-01-01	美國禮來大藥廠	平滑肌肉瘤之標靶性治療
EP3284752B1 (en) *	2015-04-16	2020-07-01	Eisai R&D Management Co., Ltd.	Anti-human notch 4 antibody
SG10201913841SA (en) *	2015-07-24	2020-03-30	Oncotracker Inc	Gamma secretase modulators for the treatment of immune system dysfunction
WO2017053705A1 (en)	2015-09-23	2017-03-30	Oncomed Pharmaceuticals, Inc.	Methods and compositions for treatment of cancer
CN105585636B (zh) *	2015-11-24	2020-03-03	南方医科大学	一种人NOTCH1 NICD蛋白Ser2162位点磷酸化抗体及其制备方法和应用
WO2017160587A1 (en)	2016-03-16	2017-09-21	Abeome Corporation	Neutralizing monoclonal antibodies to il-25 and uses thereof
EP3448420B1 (en)	2016-04-29	2022-09-14	Aveo Pharmaceuticals, Inc.	Anti-notch3 antibody
WO2017193059A1 (en)	2016-05-06	2017-11-09	The Regents Of The University Of California	Systems and methods for targeting cancer cells
WO2017205651A1 (en) *	2016-05-25	2017-11-30	The Trustees Of Columbia University In The City Of New York	Human notch1 based fusion proteins as decoy inhibitors of jagged-notch signaling and dll-notch signaling
CA3034093A1 (en)	2016-08-23	2018-03-01	The Regents Of The University Of California	Proteolytically cleavable chimeric polypeptides and methods of use thereof
JP2020500033A (ja) *	2016-11-07	2020-01-09	ザウィスターインスティテュートオブアナトミーアンドバイオロジー	ライム病に対する使用のためのｄｎａ抗体構築物
US11453718B2 (en)	2017-03-27	2022-09-27	The Schepens Eye Research Institute, Inc.	NOTCH3 agonist compositions and methods for treating small vessel diseases
US20200103419A1 (en)	2017-03-27	2020-04-02	The Schepens Eye Research Institute, Inc.	Blood biomarkers and diagnostic methods for small vessel diseases
US11325957B2 (en) *	2017-06-19	2022-05-10	Cell Design Labs, Inc.	Methods and compositions for reducing the immunogenicity of chimeric notch receptors
CN107557343B (zh) *	2017-08-09	2020-09-25	苏州大学附属儿童医院	抗人dll4单克隆抗体3f9
US11590152B2 (en)	2018-01-26	2023-02-28	Massachusetts Eye And Ear Infirmary	Treatment of hearing loss
CN112243442A (zh) *	2018-04-10	2021-01-19	桑昆血液供给基金会	嵌合Notch受体
WO2020016855A1 (en) *	2018-07-20	2020-01-23	The Hong Kong Polytechnic University	Peptides for specific inhibition of jag1-notch1 pathway
US12016885B2 (en) *	2018-11-06	2024-06-25	Alsatech, Inc.	Method of solubilizing TDP-43 protein aggregates in amyotrophic lateral sclerosis using a microvascular endothelial cell expressing an anti-TDP-43 Fab
CN111334575A (zh) *	2020-02-18	2020-06-26	至本医疗科技（上海）有限公司	Notch家族基因变异在预测实体瘤患者对免疫检查点抑制剂疗法敏感性中的应用
TW202216780A (zh) *	2020-07-17	2022-05-01	美商建南德克公司	抗ｎｏｔｃｈ２抗體及其使用方法
CN112625125B (zh) *	2021-01-18	2021-12-14	中国人民解放军军事科学院军事医学研究院	一株中和新型冠状病毒感染的单抗
TWI843989B (zh)	2021-02-19	2024-06-01	美商美威高能離子醫療系統公司	用於粒子治療系統之支架
US20240252636A1 (en) *	2021-06-24	2024-08-01	H. Lee Moffitt Cancer Center And Research Institute, Inc.	Dual egfr-muci chimeric cantigen receptor t cells
TW202340251A (zh)	2022-01-19	2023-10-16	美商建南德克公司	抗ｎｏｔｃｈ２抗體及結合物及其使用方法
CN118344474B (zh) *	2024-05-28	2024-11-15	中国农业科学院兰州兽医研究所(中国动物卫生与流行病学中心兰州分中心)	口蹄疫病毒O型、A型和Asia1型广谱中和性猪源单克隆抗体及其应用

Family Cites Families (153)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US4485045A (en)	1981-07-06	1984-11-27	Research Corporation	Synthetic phosphatidyl cholines useful in forming liposomes
US4588585A (en)	1982-10-19	1986-05-13	Cetus Corporation	Human recombinant cysteine depleted interferon-β muteins
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4544545A (en)	1983-06-20	1985-10-01	Trustees University Of Massachusetts	Liposomes containing modified cholesterol for organ targeting
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US5567610A (en)	1986-09-04	1996-10-22	Bioinvent International Ab	Method of producing human monoclonal antibodies and kit therefor
US5892019A (en)	1987-07-15	1999-04-06	The United States Of America, As Represented By The Department Of Health And Human Services	Production of a single-gene-encoded immunoglobulin
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
US5175384A (en)	1988-12-05	1992-12-29	Genpharm International	Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5013556A (en)	1989-10-20	1991-05-07	Liposome Technology, Inc.	Liposomes with enhanced circulation time
US5229275A (en)	1990-04-26	1993-07-20	Akzo N.V.	In-vitro method for producing antigen-specific human monoclonal antibodies
US5705337A (en)	1990-06-11	1998-01-06	Nexstar Pharmaceuticals, Inc.	Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US5683867A (en)	1990-06-11	1997-11-04	Nexstar Pharmaceuticals, Inc.	Systematic evolution of ligands by exponential enrichment: blended SELEX
US6344321B1 (en)	1990-06-11	2002-02-05	Gilead Sciences, Inc.	Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
US5270163A (en)	1990-06-11	1993-12-14	University Research Corporation	Methods for identifying nucleic acid ligands
US5496938A (en)	1990-06-11	1996-03-05	Nexstar Pharmaceuticals, Inc.	Nucleic acid ligands to HIV-RT and HIV-1 rev
US6172197B1 (en)	1991-07-10	2001-01-09	Medical Research Council	Methods for producing members of specific binding pairs
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
DE69133476T2 (de)	1990-08-29	2006-01-05	GenPharm International, Inc., Palo Alto	Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
CA2405246A1 (en)	1990-12-03	1992-06-11	Genentech, Inc.	Enrichment method for variant proteins with alterred binding properties
US5840867A (en)	1991-02-21	1998-11-24	Gilead Sciences, Inc.	Aptamer analogs specific for biomolecules
AU668349B2 (en) *	1991-04-25	1996-05-02	Chugai Seiyaku Kabushiki Kaisha	Reconstituted human antibody against human interleukin 6 receptor
IL101728A (en)	1991-05-03	2007-08-19	Univ Yale	Human Abandonment and Delta, Restrictive Areas of Effect in Tophoric Proteins, and Methods Based on Them
IE20030749A1 (en)	1991-05-03	2003-11-12	Indiana University Foundation	Human notch and delta binding domains in torporythmic proteins, and methods based thereon
US5582981A (en)	1991-08-14	1996-12-10	Gilead Sciences, Inc.	Method for identifying an oligonucleotide aptamer specific for a target
ES2341666T3 (es)	1991-12-02	2010-06-24	Medimmune Limited	Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US20050112121A1 (en)	1992-04-30	2005-05-26	Yale University	Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US5786158A (en) *	1992-04-30	1998-07-28	Yale University	Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US5756291A (en)	1992-08-21	1998-05-26	Gilead Sciences, Inc.	Aptamers specific for biomolecules and methods of making
DE4425115A1 (de) *	1994-07-15	1996-01-18	Boehringer Mannheim Gmbh	Verfahren zur Modifizierung der Stabilität von Antikörpern
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
US5641870A (en)	1995-04-20	1997-06-24	Genentech, Inc.	Low pH hydrophobic interaction chromatography for antibody purification
AU5752696A (en) *	1995-05-18	1996-11-29	Regents Of The University Of Michigan, The	Dna binding antibodies
US7264963B1 (en)	1995-08-18	2007-09-04	Morphosys Ag	Protein(poly)peptide libraries
ES2176484T3 (es)	1995-08-18	2002-12-01	Morphosys Ag	Bancos de proteinas/(poli)peptidos.
DE19544393A1 (de)	1995-11-15	1997-05-22	Hoechst Schering Agrevo Gmbh	Synergistische herbizide Mischungen
EP0914416B1 (en)	1996-03-30	2002-06-12	Science Park Raf S.p.A.	Method for the production of activated marked tumor-specific t cells and use thereof in treatment of tumors
EP0921818A4 (en) *	1996-05-31	2002-09-25	Nat American Red Cross	THERAPEUTIC AND DIAGNOSTIC METHODS AND COMPOSITIONS BASED ON JAGGED / NOTCH PROTEINS AND AMINO ACIDS
FR2751986B1 (fr) *	1996-08-01	1998-12-31	Inst Nat Sante Rech Med	Gene implique dans le cadasil, methode de diagnostic et application therapeutique
ATE299184T1 (de)	1996-11-07	2005-07-15	Lorantis Ltd	Notch-liganden zur verwendung in der immuntherapie
ES2246069T3 (es)	1997-05-02	2006-02-01	Genentech, Inc.	Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos.
WO1998057621A1 (en)	1997-06-18	1998-12-23	The Trustees Of Columbia University In The City Ofnew York	Angiogenic modulation by notch signal transduction
US6379925B1 (en)	1997-06-18	2002-04-30	The Trustees Of Columbia University In The City Of New York	Angiogenic modulation by notch signal transduction
US6692919B1 (en)	1997-07-23	2004-02-17	Yale University	Activated forms of notch and methods based thereon
US6004528A (en) *	1997-09-18	1999-12-21	Bergstein; Ivan	Methods of cancer diagnosis and therapy targeted against the cancer stemline
US7361336B1 (en) *	1997-09-18	2008-04-22	Ivan Bergstein	Methods of cancer therapy targeted against a cancer stem line
US20060057573A1 (en)	2002-02-15	2006-03-16	Somalogic, Inc	Methods and reagents for detecting target binding by nucleic acid ligands
CA2343963A1 (en)	1998-10-02	2000-04-13	The Government Of The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services, The National Institutes Of Health	Apotosis inducing agents and methods
US20030054360A1 (en)	1999-01-19	2003-03-20	Larry Gold	Method and apparatus for the automated generation of nucleic acid ligands
US20030003572A1 (en)	1999-03-05	2003-01-02	David J. Anderson	Isolation and enrichment of neural stem cells from uncultured tissue based on cell-surface marker expression
US20020010320A1 (en)	1999-04-05	2002-01-24	James W. Fett	Chemeric and humanized antibodies to angiogenin
ES2353268T3 (es)	1999-07-02	2011-02-28	Morphosys Ag	Generacion de elementos de union especifica que se unen a (poli)peptidos codificados por fragmentos de adn genomico o est.
US7605238B2 (en) *	1999-08-24	2009-10-20	Medarex, Inc.	Human CTLA-4 antibodies and their uses
US20030031670A1 (en) *	1999-11-08	2003-02-13	Jack R. Wands	Diagnosis and treatment of malignant neoplasms
DE10031380A1 (de)	2000-06-28	2002-01-10	Merck Patent Gmbh	Verfahren zur Übertragung von Alkyliden-Gruppen auf organischen Verbindungen
US20080194022A1 (en) *	2000-08-03	2008-08-14	Clarke Michael F	Isolation and use of solid tumor stem cells
US6984522B2 (en) *	2000-08-03	2006-01-10	Regents Of The University Of Michigan	Isolation and use of solid tumor stem cells
US8044259B2 (en) *	2000-08-03	2011-10-25	The Regents Of The University Of Michigan	Determining the capability of a test compound to affect solid tumor stem cells
AU2001288628A1 (en)	2000-08-31	2002-03-13	Loyola University Chicago	Method and reagents for treatment of skin disorders by modulating the notch pathway
US6689744B2 (en)	2000-09-22	2004-02-10	Genentech, Inc.	Notch receptor agonists and uses
EP1330544A4 (en)	2000-09-26	2005-04-06	Univ Duke	RNA APTAMERS AND METHOD OF IDENTIFYING SAID APTAMERS
JP2004517636A (ja)	2000-10-02	2004-06-17	コリアリサーチインスティテュートオブバイオサイエンスアンドバイオテクノロジー	Ｂ型肝炎ウイルスの表面抗原ｓに対するヒト化抗体及びその製造方法
JP4406206B2 (ja)	2001-04-24	2010-01-27	バイエルコーポレーション	ヒトｔｉｍｐ−１抗体
US7356224B2 (en)	2001-07-03	2008-04-08	Brown University Research Foundation	Method and apparatus for detecting multiple optical wave lengths
JP2005526701A (ja)	2001-11-14	2005-09-08	ロランティスリミテッド	内科療法
EP1461023A4 (en) *	2001-12-07	2005-08-31	Univ Michigan	Prospective Identification and Characterization of Breast Cancer Strain Cells
GB0201674D0 (en)	2002-01-25	2002-03-13	Lorantis Ltd	Medical treatment
EP2365004B1 (en)	2002-06-21	2016-01-06	Johns Hopkins University School of Medicine	Membrane associated tumor endothelium markers
DE10228103A1 (de)	2002-06-24	2004-01-15	Bayer Cropscience Ag	Fungizide Wirkstoffkombinationen
WO2004041170A2 (en) *	2002-11-01	2004-05-21	Genentech, Inc.	Compositions and methods for the treatment of immune related diseases
US20050124565A1 (en)	2002-11-21	2005-06-09	Diener John L.	Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
EP1567186A2 (en)	2002-12-06	2005-08-31	Singapore General Hospital Pte. Ltd.	Nogo, caspr, f3 and nb-3 useful in the treatment of injury and disease to the central nervous system
EP2060918A3 (en)	2003-04-01	2009-08-26	The Johns Hopkins University	Breast endothelial cell expression patterns
US7425328B2 (en)	2003-04-22	2008-09-16	Purdue Pharma L.P.	Tissue factor antibodies and uses thereof
US7563748B2 (en)	2003-06-23	2009-07-21	Cognis Ip Management Gmbh	Alcohol alkoxylate carriers for pesticide active ingredients
US7329742B2 (en)	2003-09-04	2008-02-12	The Regents Of The University Of California	Aptamers and methods for their in vitro selection and uses thereof
GB0321805D0 (en)	2003-09-18	2003-10-15	Univ Wales Medicine	Human tumour growth patterns
US7282203B2 (en)	2003-11-26	2007-10-16	Health Research, Inc.	Use of NOTCH pathway interfering agents for treatment of plasma cell disorders
AU2005209909B8 (en)	2004-02-03	2009-01-15	The Regents Of The University Of Michigan	Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
FR2867784B1 (fr)	2004-03-17	2006-06-09	Commissariat Energie Atomique	Aptameres selectionnes a partir de cellules vivantes tumorales et leurs applications
WO2005090981A2 (en)	2004-03-24	2005-09-29	Technion Research & Development Foundation Ltd.	Electrode
US20050239134A1 (en)	2004-04-21	2005-10-27	Board Of Regents, The University Of Texas System	Combinatorial selection of phosphorothioate single-stranded DNA aptamers for TGF-beta-1 protein
WO2005111072A2 (en) *	2004-04-29	2005-11-24	The Trustees Of Columbia University In The City Of New York	Notch-based fusion proteins and uses thereof
RU2346996C2 (ru)	2004-06-29	2009-02-20	ЮРОПИЭН НИКЕЛЬ ПиЭлСи	Усовершенствованное выщелачивание основных металлов
US20070077245A1 (en)	2004-08-04	2007-04-05	The Brigham And Women's Hospital, Inc.	NOTCH mutations leading to increased receptor signaling
GB0421838D0 (en) *	2004-09-30	2004-11-03	Congenia S R L	Cancer markers
WO2006053063A2 (en)	2004-11-05	2006-05-18	The Regents Of The University Of California	Notch-1 assay to detect neurodegenerative diseases
US20070265246A1 (en) *	2004-11-10	2007-11-15	Clevers Johannes C	Treatment of an Intestinal Adenoma and/or Adenocarcinoma by Inhibition of Notch Pathway Activation
CA3218940A1 (en)	2004-11-12	2006-05-18	Cambridge University Technical Services Ltd.	Methods and means related to cancer stem cells
US20090220495A1 (en)	2005-04-07	2009-09-03	Abdallah Fanidi	Cancer Related Genes (PRLR)
AU2006264212B2 (en)	2005-06-29	2010-10-28	Compumedics Limited	Sensor assembly with conductive bridge
US7723112B2 (en)	2005-10-31	2010-05-25	The Regents Of The University Of Michigan	Compositions and methods for treating and diagnosing cancer
WO2007061988A2 (en)	2005-11-22	2007-05-31	University Of Vermont And State Agricultural College	Methods for determining notch signaling and uses thereof
CA2630839C (en)	2005-12-16	2017-01-17	Regeneron Pharmaceuticals, Inc.	Therapeutic methods for inhibiting tumor growth with dll4 antagonists
WO2007075915A2 (en)	2005-12-22	2007-07-05	The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Monoclonal antibodies against orthopoxviruses
AR059922A1 (es) *	2006-04-01	2008-05-07	Galaxy Biotech Llc	Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
US20080241150A1 (en)	2006-05-15	2008-10-02	The Brigham And Women's Hospital, Inc.	Functional negative regulatory domain sequences from human NOTCH1 and 2 and isolated LNR domains from human NOTCH1
US7803377B2 (en)	2006-06-06	2010-09-28	Genentech, Inc.	Anti-DLL4 antibodies and methods using same
JP2009539870A (ja)	2006-06-06	2009-11-19	ジェネンテック・インコーポレーテッド	血管発生の調節ための組成物および方法
WO2007145840A2 (en)	2006-06-13	2007-12-21	Oncomed Pharmaceuticals, Inc.	Compositions and methods for diagnosing and treating cancer
TW200801513A (en)	2006-06-29	2008-01-01	Fermiscan Australia Pty Ltd	Improved process
JP5535633B2 (ja) *	2006-09-29	2014-07-02	オンコメッドファーマシューティカルズインコーポレイテッド	癌の診断および処置のための組成物および方法
WO2008050525A1 (en)	2006-09-29	2008-05-02	Konica Minolta Opto, Inc.	Retardation film
WO2008136848A2 (en)	2006-10-19	2008-11-13	Genentech Inc.	Novel anti-notch3 antibodies and their use in the detection and diagnosis of disease
US7700113B2 (en) *	2006-10-19	2010-04-20	Maine Medical Research Institute, A Division Of Maine Medical Center	Inhibiting breast cancer cell growth by administering an intracellular domain of NOTCH2
EP2087006B1 (en)	2006-10-19	2016-06-08	Genentech, Inc.	Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
WO2008057114A1 (en)	2006-11-06	2008-05-15	Howard Shapiro	Management of teaching processes for individualized instruction in a multi-student environment
NO347649B1 (no)	2006-12-14	2024-02-12	Regeneron Pharma	Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
CA2670992C (en)	2006-12-18	2017-11-21	Genentech, Inc.	Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases
EP2120996A2 (en)	2006-12-20	2009-11-25	Vasgene Therapeutics, Inc.	Methods for using and identifying modulators of delta-like 4
JP5618544B2 (ja)	2007-01-24	2014-11-05	オンコメッドファーマシューティカルズインコーポレイテッド	癌の診断および処置のための組成物および方法
JP2010517944A (ja)	2007-01-26	2010-05-27	バイオインヴェントインターナショナルアーベー	Ｄｌｌ４シグナリング阻害薬およびその使用
WO2008100563A2 (en)	2007-02-14	2008-08-21	Oncomed Pharmaceuticals, Inc.	Compositions and methods for diagnosing and treating cancer
US20100099090A1 (en) *	2007-03-05	2010-04-22	Bristol-Mayers Squibb Company	Biomarkers and methods for determining sensitivity to ctla-4 antagonists
JP2010520280A (ja)	2007-03-05	2010-06-10	ボードオブリージェンツ，ザユニバーシティオブテキサスシステム	ＮｏｔｃｈまたはＮｕｍｂ特異的免疫療法との相乗効果を有する、癌細胞の再生のネガティブな遺伝的制御
PE20090321A1 (es)	2007-06-04	2009-04-20	Genentech Inc	Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
TWI392503B (zh) *	2007-07-16	2013-04-11	建南德克公司	抗－ｃｄ７９ｂ抗體及免疫共軛物及使用方法
MX2010002053A (es)	2007-08-23	2010-07-28	Univ Columbia	Composiciones de proteinas de fusion de notch humanizadas y metodos de tratamiento.
WO2009032084A1 (en)	2007-08-28	2009-03-12	Merck & Co., Inc.	Expression profiles of biomarker genes in notch mediated cancers
US8377886B2 (en)	2007-09-14	2013-02-19	Albert Einstein College Of Medicine Of Yeshiva University	Use of gamma secretase inhibitors and notch pathway inhibitors for treatment and prevention of renal disease
US7807630B2 (en)	2007-09-14	2010-10-05	Vanderbilt University	Targeting of Notch3 receptor function for cancer therapy
US20120082659A1 (en)	2007-10-02	2012-04-05	Hartmut Land	Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
US8119366B2 (en)	2007-10-05	2012-02-21	Trojan Technologies, Ltd.	Antennapedia-dominant negative mastermind-like construct
CN102056945A (zh)	2008-04-07	2011-05-11	埃博灵克斯股份有限公司	针对Notch途径的单可变结构域
WO2010000020A1 (en)	2008-06-30	2010-01-07	Cathrx Ltd	A catheter
US9132189B2 (en)	2008-07-08	2015-09-15	Oncomed Pharmaceuticals, Inc.	Notch1 binding agents and methods of use thereof
NZ590127A (en)	2008-07-08	2012-11-30	Oncomed Pharm Inc	Notch1 receptor binding agents and methods of use thereof
BRPI0913827A2 (pt)	2008-10-01	2020-12-29	Genentech, Inc	Anticorpo monoclonal, método para inibir a atividade de notch2, método para tratar uma doença, método para tratar uma malignidade, método para tratar um melanoma, usos de um anticorpo e anticorpo nrr anti-notch2
US8425930B2 (en)	2009-03-13	2013-04-23	The Regents Of The University Of California	Prebiotic oligosaccharides
CA2775880A1 (en)	2009-09-30	2011-04-07	Genentech, Inc.	Anti-notch3 antagonist antibodies to treat gamma secretase inhibitor responsive and anti-notch1 antagonist antibody unresponsive t-cell leukemias
DE102009047243A1 (de)	2009-11-27	2011-06-01	Orgentec Diagnostika Gmbh	Monospezifische Polypeptidreagenzien
AU2011205316B2 (en)	2010-01-13	2015-05-28	Oncomed Pharmaceuticals, Inc.	Notch1 binding agents and methods of use thereof
SG183196A1 (en)	2010-02-12	2012-09-27	Oncomed Pharm Inc	Methods for identifying and isolating cells expressing a polypeptide
JP5450221B2 (ja)	2010-04-14	2014-03-26	株式会社神戸製鋼所	高電流密度ガスシールドアーク溶接方法
CN107011438B (zh)	2010-05-04	2020-11-20	戊瑞治疗有限公司	结合csf1r的抗体
WO2012003472A1 (en)	2010-07-02	2012-01-05	Aveo Pharmaceuticals, Inc.	Anti-notch1 antibodies
PT3556774T (pt)	2011-03-11	2024-02-29	Beth Israel Deaconess Medical Ct Inc	Anticorpos anti-cd40 e suas utilizações
CA2864197A1 (en)	2011-11-16	2013-05-23	Oncomed Pharmaceuticals, Inc.	Human notch receptor mutations and their use
EP2849785A4 (en)	2012-05-16	2015-12-16	Oncomed Pharm Inc	METHOD FOR THE TREATMENT OF CANCER WITH NOTCH2 / 3 ANTIBODIES
EP2892524B1 (en)	2012-09-04	2020-11-25	Eleison Pharmaceuticals, LLC	Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin
US20150232570A1 (en)	2012-09-21	2015-08-20	Oncomed Pharmaceuticals, Inc.	Methods of Treating Hematological Malignancies with Notch1 Antibodies
TW201726746A (zh)	2012-11-07	2017-08-01	輝瑞股份有限公司	抗切口３（ａｎｔｉ-ｎｏｔｃｈ３）抗體及抗體-藥物共軛體
KR20150130466A (ko)	2013-03-15	2015-11-23	온코메드 파마슈티칼스, 인크.	췌장암을 치료하는 방법
CN106659778A (zh)	2014-03-07	2017-05-10	昂考梅德药品有限公司	用Notch1抗体治疗癌症的方法
US20170023576A1 (en)	2014-04-04	2017-01-26	Oncomed Pharmaceuticals, Inc.	Notch3 antibodies and uses thereof

2009
- 2009-07-08 NZ NZ590127A patent/NZ590127A/xx not_active IP Right Cessation
- 2009-07-08 EP EP14195878.5A patent/EP2899211A1/en not_active Withdrawn
- 2009-07-08 MY MYPI2011000057A patent/MY159815A/en unknown
- 2009-07-08 JP JP2011517417A patent/JP5560271B2/ja not_active Expired - Fee Related
- 2009-07-08 SG SG2013051586A patent/SG192468A1/en unknown
- 2009-07-08 DK DK09794821.0T patent/DK2307051T3/en active
- 2009-07-08 MY MYPI2011000058A patent/MY155603A/en unknown
- 2009-07-08 EP EP14199035.8A patent/EP2924051A1/en not_active Withdrawn
- 2009-07-08 EP EP09794822.8A patent/EP2307459B1/en active Active
- 2009-07-08 SI SI200931156T patent/SI2307051T1/sl unknown
- 2009-07-08 WO PCT/US2009/003994 patent/WO2010005566A2/en not_active Ceased
- 2009-07-08 BR BRPI0914007A patent/BRPI0914007A2/pt not_active IP Right Cessation
- 2009-07-08 MX MX2011000233A patent/MX2011000233A/es active IP Right Grant
- 2009-07-08 US US12/499,627 patent/US8226943B2/en not_active Expired - Fee Related
- 2009-07-08 CN CN201410524761.7A patent/CN104402998A/zh active Pending
- 2009-07-08 HR HRP20150256AT patent/HRP20150256T1/hr unknown
- 2009-07-08 CA CA2729602A patent/CA2729602A1/en not_active Abandoned
- 2009-07-08 US US13/003,013 patent/US8435513B2/en not_active Expired - Fee Related
- 2009-07-08 JP JP2011517416A patent/JP5560270B2/ja not_active Expired - Fee Related
- 2009-07-08 SI SI200931146T patent/SI2307459T1/sl unknown
- 2009-07-08 HR HRP20150443TT patent/HRP20150443T1/hr unknown
- 2009-07-08 BR BRPI0914004A patent/BRPI0914004A2/pt not_active IP Right Cessation
- 2009-07-08 KR KR1020117000743A patent/KR101682490B1/ko not_active Expired - Fee Related
- 2009-07-08 KR KR1020117000736A patent/KR101640099B1/ko not_active Expired - Fee Related
- 2009-07-08 ES ES09794821.0T patent/ES2535614T3/es active Active
- 2009-07-08 ME MEP-2015-63A patent/ME02148B/me unknown
- 2009-07-08 AU AU2009269095A patent/AU2009269095B2/en not_active Ceased
- 2009-07-08 MX MX2011000236A patent/MX2011000236A/es active IP Right Grant
- 2009-07-08 EP EP09794821.0A patent/EP2307051B1/en active Active
- 2009-07-08 RS RS20150288A patent/RS53924B1/sr unknown
- 2009-07-08 EA EA201170157A patent/EA201170157A1/ru unknown
- 2009-07-08 CN CN200980126470.XA patent/CN102316897B/zh not_active Expired - Fee Related
- 2009-07-08 PL PL09794822T patent/PL2307459T3/pl unknown
- 2009-07-08 WO PCT/US2009/003995 patent/WO2010005567A2/en not_active Ceased
- 2009-07-08 SG SG2013051578A patent/SG192467A1/en unknown
- 2009-07-08 ME MEP-2015-20A patent/ME02069B/me unknown
- 2009-07-08 PL PL09794821T patent/PL2307051T3/pl unknown
- 2009-07-08 EA EA201170158A patent/EA026109B1/ru not_active IP Right Cessation
- 2009-07-08 RS RS20150120A patent/RS53750B1/sr unknown
- 2009-07-08 PT PT97948210T patent/PT2307051E/pt unknown
- 2009-07-08 CA CA2729306A patent/CA2729306C/en not_active Expired - Fee Related
- 2009-07-08 DK DK09794822.8T patent/DK2307459T3/da active
- 2009-07-08 CN CN200980126471.4A patent/CN102112490B/zh not_active Expired - Fee Related
- 2009-07-08 PT PT09794822T patent/PT2307459E/pt unknown
- 2009-07-08 NZ NZ590131A patent/NZ590131A/xx not_active IP Right Cessation
- 2009-07-08 ES ES09794822.8T patent/ES2531541T3/es active Active
- 2009-08-07 UA UAA201101442A patent/UA101672C2/uk unknown
2010
- 2010-12-23 IL IL210222A patent/IL210222A/en not_active IP Right Cessation
- 2010-12-23 IL IL210221A patent/IL210221A/en not_active IP Right Cessation
- 2010-12-23 ZA ZA2010/09280A patent/ZA201009280B/en unknown
2011
- 2011-01-03 MA MA33483A patent/MA32448B1/fr unknown
- 2011-01-03 ZA ZA2011/00029A patent/ZA201100029B/en unknown
- 2011-01-03 MA MA33484A patent/MA32449B1/fr unknown
- 2011-01-05 DO DO2011000004A patent/DOP2011000004A/es unknown
- 2011-01-05 DO DO2011000002A patent/DOP2011000002A/es unknown
- 2011-02-07 CR CR20110069A patent/CR20110069A/es unknown
- 2011-02-08 CO CO11014588A patent/CO6390041A2/es active IP Right Grant
- 2011-02-08 CO CO11014579A patent/CO6612253A2/es active IP Right Grant
2012
- 2012-05-15 US US13/472,305 patent/US8425903B2/en not_active Expired - Fee Related
2013
- 2013-03-01 US US13/782,671 patent/US8945873B2/en not_active Expired - Fee Related
- 2013-03-13 US US13/801,613 patent/US8945874B2/en not_active Expired - Fee Related
- 2013-03-14 US US13/826,284 patent/US8945547B2/en active Active
- 2013-03-14 US US13/826,432 patent/US8980260B2/en active Active
2014
- 2014-12-19 US US14/577,484 patent/US9499613B2/en not_active Expired - Fee Related
2015
- 2015-01-20 US US14/600,641 patent/US9505832B2/en active Active
- 2015-03-02 SM SM201500047T patent/SMT201500047B/xx unknown
- 2015-03-03 CY CY20151100227T patent/CY1116195T1/el unknown
- 2015-04-24 CY CY20151100376T patent/CY1116230T1/el unknown
- 2015-05-20 SM SM201500120T patent/SMT201500120B/xx unknown
2016
- 2016-08-16 AU AU2016216568A patent/AU2016216568A1/en not_active Abandoned
- 2016-10-12 US US15/291,334 patent/US20170183405A1/en not_active Abandoned
- 2016-10-20 US US15/298,527 patent/US20170198031A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP2899211A1 (en)	2015-07-29
CY1116195T1 (el)	2017-02-08
KR20110031315A (ko)	2011-03-25
DOP2011000002A (es)	2011-04-15
JP5560270B2 (ja)	2014-07-23
MX2011000236A (es)	2011-02-24
CN102112490A (zh)	2011-06-29
CA2729602A1 (en)	2010-01-14
CO6612253A2 (es)	2013-02-01
US8945874B2 (en)	2015-02-03
HK1151218A1 (en)	2012-01-27
EP2924051A1 (en)	2015-09-30
IL210221A0 (en)	2011-03-31
EA201170158A1 (ru)	2011-08-30
SMT201500120B (it)	2015-07-09
US8226943B2 (en)	2012-07-24
US20140011271A1 (en)	2014-01-09
PL2307459T3 (pl)	2015-05-29
CN102112490B (zh)	2014-10-22
AU2009269095A1 (en)	2010-01-14
US20100111958A1 (en)	2010-05-06
AU2009269096A1 (en)	2010-01-14
US8435513B2 (en)	2013-05-07
RS53924B1 (sr)	2015-08-31
JP2012501625A (ja)	2012-01-26
US8425903B2 (en)	2013-04-23
HRP20150256T1 (hr)	2015-04-10
EA026109B1 (ru)	2017-03-31
AU2016216568A1 (en)	2016-09-01
WO2010005567A3 (en)	2010-05-27
NZ590131A (en)	2012-10-26
EP2307051A2 (en)	2011-04-13
SI2307459T1 (sl)	2015-04-30
US20150197563A1 (en)	2015-07-16
US20130260455A1 (en)	2013-10-03
DOP2011000004A (es)	2011-04-15
CA2729306A1 (en)	2010-01-14
SMT201500047B (it)	2015-05-05
EP2307459A4 (en)	2012-07-18
ZA201009280B (en)	2012-04-25
US20130296536A1 (en)	2013-11-07
CY1116230T1 (el)	2017-02-08
BRPI0914007A2 (pt)	2015-11-17
KR101640099B1 (ko)	2016-07-15
PT2307459E (pt)	2015-03-11
HRP20150443T1 (hr)	2015-05-22
US20170198031A1 (en)	2017-07-13
WO2010005566A3 (en)	2010-09-16
ME02148B (me)	2015-10-20
US20170183405A1 (en)	2017-06-29
US8980260B2 (en)	2015-03-17
ES2531541T3 (es)	2015-03-17
AU2009269096B2 (en)	2016-05-12
MX2011000233A (es)	2011-05-19
US9505832B2 (en)	2016-11-29
ES2535614T3 (es)	2015-05-13
CO6390041A2 (es)	2012-02-29
EP2307459B1 (en)	2015-01-07
US8945547B2 (en)	2015-02-03
US20110311552A1 (en)	2011-12-22
CA2729306C (en)	2015-08-18
CN102316897A (zh)	2012-01-11
WO2010005566A2 (en)	2010-01-14
DK2307459T3 (da)	2015-02-09
AU2009269095B2 (en)	2016-05-19
SG192467A1 (en)	2013-08-30
IL210221A (en)	2014-02-27
US8945873B2 (en)	2015-02-03
KR20110028621A (ko)	2011-03-21
CR20110069A (es)	2011-07-11
PT2307051E (pt)	2015-05-21
EP2307459A2 (en)	2011-04-13
IL210222A (en)	2016-05-31
MY159815A (en)	2017-02-15
EP2307051B1 (en)	2015-02-11
HK1151296A1 (en)	2012-01-27
MA32449B1 (fr)	2011-07-03
ME02069B (me)	2015-05-20
ZA201100029B (en)	2012-03-28
US20130280277A1 (en)	2013-10-24
CN104402998A (zh)	2015-03-11
RS53750B1 (sr)	2015-06-30
CN102316897B (zh)	2014-11-05
SI2307051T1 (sl)	2015-04-30
MA32448B1 (fr)	2011-07-03
DK2307051T3 (en)	2015-04-20
EA201170157A1 (ru)	2011-08-30
JP2012501626A (ja)	2012-01-26
US9499613B2 (en)	2016-11-22
IL210222A0 (en)	2011-03-31
EP2307051A4 (en)	2012-07-18
US20150166963A1 (en)	2015-06-18
PL2307051T3 (pl)	2015-07-31
NZ590127A (en)	2012-11-30
MY155603A (en)	2015-11-13
SG192468A1 (en)	2013-08-30
US20120288496A1 (en)	2012-11-15
WO2010005567A2 (en)	2010-01-14
JP5560271B2 (ja)	2014-07-23
UA101672C2 (uk)	2013-04-25
KR101682490B1 (ko)	2016-12-05

Publication	Publication Date	Title
BRPI0914004A2 (pt)	2015-11-17	agentes de aglutinação de receptor notch1 e métodos de uso mesmo
CY2023024I1 (el)	2024-02-16	Παραγοντες προσδεσης του psma και χρησεις αυτων
BRPI0820387A2 (pt)	2015-05-26	Agentes de ligação de wise e epítopos
BRPI0911563A2 (pt)	2016-07-12	uso de antagonista da progesterona
BRPI0906478A2 (pt)	2015-11-24	anticorpo anti-nr10 e uso do mesmo
BRPI0821668A2 (pt)	2015-06-16	Uso
BRPI0813627A2 (pt)	2014-12-23	Peptídio antimicrobiano, composições e métodos de uso
BRPI0915717A2 (pt)	2015-10-27	ferramenta de avaliação de cascalho e métodos de uso
DK2349430T3 (da)	2019-11-11	KATETERISERINGANORDNING og -kit
BRPI0821090A2 (pt)	2015-06-16	Moduladores seletivos de receptores de androgênio (sarms) e uso do mesmo
BRPI0912703A2 (pt)	2017-06-13	composições imuno-moduladoras e métodos para uso dessas
BRPI0808684A2 (pt)	2016-11-01	moduladores de tgr5 e métodos de uso destes
BRPI0820819A2 (pt)	2015-06-16	Formulação de anticorpos
BRPI0909954A2 (pt)	2015-11-03	"diazacarbazóis e métodos de uso"
BRPI0913188A2 (pt)	2016-01-12	moduladores de receptores 5-ht3, métodos de fabricação, e uso dos mesmos
DOP2010000260A (es)	2010-10-15	Derivado heterociclico fusionado y su uso
HRP20180718T1 (hr)	2018-07-13	Oligopeptidni spojevi i njihova upotreba
BRPI0811137A2 (pt)	2014-12-23	Método, e, dispositivo de usuário
BRPI0816835A2 (pt)	2016-08-02	dispositivo de pulverização e método de uso do mesmo
BRPI0806964A2 (pt)	2014-04-08	Combinações de agonístico beta-2-adrenoceptor e benzotiazolona
BRPI0919794A2 (pt)	2015-12-15	dispositivo para uso intracorpóreo, e, composto
BRPI0813457A2 (pt)	2014-12-23	Composto de organoenxofre contendo halogênio e uso do mesmo
BRPI0909840A2 (pt)	2015-07-28	Uso de 4-tio-2-deoxinucleosídios
BRPI0913325A2 (pt)	2015-11-17	interface de usuário para dispositivo de teste
BRPI1009257A2 (pt)	2016-03-08	antagonista receptor de mineralocorticoide e métodos de uso.

Legal Events

Date	Code	Title
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-05-02	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
2018-08-21	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]